Admin Posted March 4, 2018 Share Posted March 4, 2018 Jim Marshall (not a doctor) said ... Xofigo (Radium-223) has been recommended to go on the PBS. The conditions just published include: Previous Docetaxel, or unsuitability for Docetaxel; No previous enzalutamide (Xtandi) (or intolerance); No previous abiraterone (Zytiga) (or intolerance); So if a man has 2 or more bone metastases (mets) on the PBS his doctor will have to choose only one of: Xtandi (enzalutamide); Zytiga (abiraterone); Xofigo (Radium-233). If a man does not qualify for PBS Xofigo, doses cost about $7,000, with up to 6 doses the normal treatment. ... end Jim From the Public Summary Document – November 2017 PBAC Meeting Patients must have ≥ 2 skeletal metastases AND Patient must have a WHO performance status of 2 or less AND Patient must have failed treatment with docetaxel due to resistance or intolerance; OR Patient must be unsuitable for docetaxel treatment on the basis of predicted intolerance to docetaxel AND The treatment must not be used in combination with chemotherapy. AND The patient must not receive PBS-subsidised 223Ra if progressive disease develops while on 223Ra AND The patient must not have received prior treatment with abiraterone or enzalutamide; OR The patient must have developed intolerance to enzalutamide requiring permanent withdrawal AND The patient must have developed intolerance to abiraterone requiring permanent withdrawal. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.